MR imaging of gene transcription is important as it should enable the non-invasive detection of mRNA alterations in disease. A range of MRI methods have been proposed for in vivo molecular imaging of cells based on the use of ultra- small super-paramagnetic iron oxide (USPIO) nanoparticles and related susceptibility weighted imaging methods. Al-though immunohistochemistry can robustly differentiate the expression of protein variants, there is currently no direct gene assay technique that is capable of differentiating established to differentiate the induction profiles of c-Fos mRNA in vivo. To visualize the differential FosB gene expression profile in vivo after burn trauma, we developed MR probes that link the T2* contrast agent [superparamagnetic iron oxide nanoparticles (SPION)] with an oligodeoxynucleotide (ODN) sequence complementary to FosB mRNA to visualize endogenous mRNA targets via in vivo hybridization. The presence of this SPION-ODN probe in cells results in localized signal reduction in T2*-weighted MR images, in which the rate of signal reduction (R2*) reflects the regional iron concentration at different stages of amphetamine (AMPH) exposure in living mouse tissue. Our aim was to produce a superior contrast agent that can be administered using sys- temic as opposed to local administration and which will target and accumulate at sites of burn injury. Specifically, we developed and evaluated a PEGylated lipid coated MR probe with ultra-small super-paramagnetic iron oxide nanoparti- cles (USPION, a T2 susceptibility agent) coated with cationic fusogenic lipids, used for cell transfection and gene de- livery and covalently linked to a phosphorothioate modified oligodeoxynucleotide (sODN) complementary to c-Fos mRNA (SPION-cFos) and used the agent to image mice with leg burns. Our study demonstrated the feasibility of monitoring burn injury using MR imaging of c-Fos transcription in vivo, in a clinically relevant mouse model of burn injury for the first time.
The well-known proto-oncogene, c-Fos, encodes a protein that plays key role in every kind of oxidative stress including burn trauma. It has been reported that burns up-regulate the expression of c-Fos within six hours after injury and that this process is mediated through signals originating from the nucleus of monocytes and dermal fibroblasts. This up-regulation is mediated by the effect of protein growth factors that stimulate transcriptional activity and increase the delivery of Mrna to the cytoplasm [1-3]. Since c-Fos activation is implicated in numerous crucial intracellular functions such as cell cycle activity and apoptosis, regulation of signal transduction pathways, cellular trafficking, cell proliferation and differentiation, cell survival, and protein folding and proessing and its detection is important in establishing the pathology and path-physiology of burn and the regenerative processes [
Imaging of c-Fos in neural tissues has been reported and it employs ultra-paramagnetic spion agents conjugated to complimentary sODNs. These contrast agents have been employed successfully for magnetic imaging in vivo by local administration to the brain and the use of cell transfection agents as lipofectin [7-9]. Since lpofectin is a generic agent imaging can be performed only after a waiting period and the results obtained following a kinetic study. This imaging method has been limited only to brain tissue since its effectiveness is limited by the transfection capacity of the co-administered agent [
Lipid coated nanoparticles have been well established to induce gene transfection in vivo. The application of fusogenic lipids induces fusion of the nanoparticle to the cell membrane allowing the contents of the particle to enter the cells [
Lipid coated nanoparticles have also been used for optical imaging in vivo. The lipid coating is changing fundamentally the bio-distribution and the site accumulation of the nanoparticles, leading to self-targeting to the desired site within a few hours. It was demonstrated that similar lipid coated nanoparticles accumulate rapidly to the desired sites and clear form the site with equal speed following their peak concentration at one hour [22,23], while they cannot be detected at four hours following their i.v. administration, a much faster biodistribution compared to the conventional, non-lipid coated solid nanoparticles.
Our aim here was to produce a superior contrast agent that can be administered via systemic injection as oposed to local administration, and will target and accumulate at sites of burn injury. Following the successful accumulation and transfection of the cells by the fusogenic lipid coating, the mRNA expression was imaged and quantified in vivo. Specifically, we developed a pegylated lipid coated MR probe with ultra-small super-paramagnetic iron oxide nanoparticles (USPION, a T2 susceptibility agent) coated with polymer modified fusogenic lipids and covalently linked to a phosphorothioate-modified oligodeoxynucleotide (sODN) complementary to c-Fos mRNA (SPION-c-Fos) and imaged mice with leg burn. Our study demonstrates the feasibility to monitor burn injury using MR imaging of c-Fos transcription in vivo, in a clinically relevant mouse model of burn trauma for the first time.
Ultra-small super-paramagnetic iron-oxide nanoparticles (USPIO): Synthetic ultra-small super-paramagnetic iron- oxide particles, known generically as Ferumoxtran-10 (USPIO) commercially and as Combidex® in the U.S. (Advanced Magnetics, Cambridge, MA), were used as a molecular-imaging MRI contrast agent. Ferumoxtran-10 nanoparticles are composed of monocrystalline sperparamagnetic iron-oxide magnetite (Fe3O4) cores of about 5 nm diameter, and they are coated with a dense packing of low molecular weight dextrans to prolong their time in circulation, resulting in a hydrodynamic diameter of about 30 nm.
Contrast agent was prepared by the thin layer evaporation method with slight modifications [
The conjugates were evaluated using a gel shift assay, as described previously [
In vivo imaging was performed in a 4.7 T horizontal magnet (20 cm bore, Bruker Avance console) equipped with gradient system capable of 39 G/cm, using a custom-built volume coil of 3 cm inner diameter and 10 cm active length. Shimming was performed using two repetitions of the automated shimming procedure, followed by manual shimming when necessary (typical water linewidth, ~15 - 20 Hz). We used a clinically relevant mouse model of burn injury [
At the MR scanner, mice were anesthetized with a mixture of isoflurane (2.0%) and O2 (2.0 l/min). Following induction of anesthesia and for the duration of MR imaging, the mice were kept anesthetized with a mixture of isoflurane (1.5%) and O2 (0.6 l/min). The mouse body temperature was maintained at 37˚C with a warm water blanket.
Anatomical reference images were acquired with RARE (Rapid Acquisition with Refocused Echo) [
The image intensity at each voxel was divided by the image noise level. Image noise level was estimated from fitting the histogram of an area in the image background, containing only pure noise voxels, to a Rician distribution. Accordingly, the value of three standard deviations was chosen to threshold-out Rician-noise voxels. An ROI was drawn at the level of the burn area for each mouse, and the total above-threshold signal enclosed in the ROI was computed.
Statistical Analysis: For ROI analysis, we selected MR slices from MR data of each animal group for t-test statistical analysis (two-tailed Student’s t-test, n = 6 per group).
Thus, Figures 3 and 4 represent the signal to noise detected from the five animals in different echo times, following the injection of the contrast agent. As evident from the figures, there is always higher signal from the burned site compared to that of the control site, following the administration of the contrast agent via the tail vein. Furthermore,
Imaging c-Fos expresion in burns offers a unique advantage over other detection methods. It is simple to perform, more reliable and allows for results in real time. Here, we employed a T2* weighting imaging method because our agent is a T2* susceptibility agent. We used supermaramgentic iron nanoparticles, a T2* susceptibility agent, as used by us before [
Our methodology has unique advantages that includeeasy of use and applicability for systemic administration. Previously reported use of similar SPION agents was focused on the gene expression in brain [8,9,29-31] (In these studies, specificity was demonstrated using agents with beta-act-in mRNA and random sequence ODNs). In addition the contrast agents had to be administrated locally behind the eye and cell transfection was accomplished using generic agents such as lipofectin and accumulation at the target site is non specific in nature. In fact transfetion is generic and mRNA bound to spions could be imaged only after twelve hours when unbound tracer was released from the cells. Thus, detection of gene expression required a kinetic study of the accumulation and imaging results were correlated to the actual gene expression only after a wash out period. Our methodology is far superior because it allows for transfection at only the pathological site, as only burned tissue attract nanoparticles. Therefore, as evident from the control site, imaging of gene expression took place only at the area of injury.
The motivation behind our work was that c-Fos expression was never imaged in burns, although there are several publications indicating that c-Fos expression can be imaged in cerebral tissue in a variety of pathological conditions. We developed a novel lipid modified contrast agent to label non-invasively the mRNA transcription. Our methodology was to image the gene expression for one day following the administration of the contrast agent in accordance with the protocol established for the gene expression imaging in cerebral tissue and our previous experience with lipid modified contrast agents [7-9, 30,31]. Since we have already established that lipid coated metal nanoparticles accumulate within 2 hours at their target site [19,22,23] and that one day is a sufficient clearance time for non-DNA bond SPIONS, we followed this experimental procedure. Acquisition times were less than 10 min per scan while the retention of contrast agents is published to be several days at their binding site. However, in this study we only performed the experiment at one time point. To this end we have no date on a time series. Nevertheless, based on our data, we may speculate that our procedure will facilitate burn injury monitoring.
Our system tracks and images the gene expression in situ and in real time. As our collaborators have previously indicated [8,9,31] the ability of the contrast agent to track and quantify the gene expression was verified with iron oxide labeling and histology, c-Fos targeting, FITC labelling, and in situ DNA hybridization, as well as comparing the treatment and control sites at the same animals. This system has also been used to trace and track the gene expression for several hours in brain tissue. Following its modification with a self internalizing lipid coating its use can be expanded to a variety of situations and conditions including burn injury, where non invassive system in administration could be advantageous and desired.
Our experimental set-up is designed to demonstrate both the benefits of the contrast agent and that of the imaging sequence. As evident from our results, we constantly observe a higher signal from the burned site than the control and this is also depicted in the cumulative results. This is mainly due to the unique advantages of our positive contrast methodology [
Lipid coated nano-particles accumulate to the target site via passive accumulation with extended permeation and retention effects. Accumulation of our micelle-like formulation at the target site takes place in less than one hour and the remaining time before imaging was required for intracellular accumulation of the agent. We were able to employ the same technique using a different lipid composition to achieve both accumulating at the target site and cell transfection using cationic lipids. This is another advantage of this formulation as it simplifies a multi-step procedure for cell transfection to a single step. Furthermore cationic lipids are highly biocompatible so that once inside the cells, the contrast agent is expected to allow imaging of the mRNA for many hours [8,9]. Our previously reported results indicate that for micellar nano-particles, accumulation at the target site via extended permeation and retention effects takes place within the first hour after administration and clearance is completed within four hours. Since imaging is performed much later, the only conclusion is that the nano-particles have been successfully administered and follow mRNA expression. This conclusion is further substantiated by previous reports that spions administrated with fusogenic agents have a generic cellular transfection pattern which after twelve hours is limited to cells expressing c-Fos as demonstrated with gel electrophoresis [8,9].
Previously, cationic lipids have been mainly used for treatment of pathological conditions by gene delivery and siRNA transfection in vivo [32-35]. In these situations the osDNA is required to remain functional and active during the accumulation time to the desired site. Therefore the cationic lipids are used both for protection of the cargo, targeting to the desired site and accumulation inside the cells. Furthermore our results indicate that the DNA is active since it allows for the detection of gene expression. This contrast agent therefore presents a major improvement in the field of lipid coated solid nano-particles and it can be further developed for imaging gene expression in a variety of human conditions.
Our study demonstrates the feasibility of monitoring burn injury using MR imaging of c-Fos transcription in vivo, in a clinically relevant mouse model of burn trauma for the first time. It opens the pathway for MR imaging of the expression of other genes important for monitoring treatments of burn injuries. Our findings represent a new line of research that can support the development of novel therapeutics in the molecular medicine of burn injury. Such therapeutics would have wide-spread applications not only for burn patients, but also for many individuals suffering from other chronic or end stage diseases that exhibit muscle wasting, a condition for which only marginally effective treatments are currently available. Our imminent interest is to perform experiments using novel therapeutic agents for burns and other chronic diseases for monitoring the expression of key regulatory genes such as uncoupling proteins.
This study was supported by Shriner’s Hospital for Children research grants (No. 8893) to A. Aria Tzika, and (No. 8892) to Laurence G. Rahme and also in part by a National Institutes of Health (NIH) Center Grant (P50GM 021700) to Ronald G. Tompkins (A. Aria Tzika, Director of the NMR core).